Patents Assigned to GemVax AS
  • Publication number: 20160008438
    Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.
    Type: Application
    Filed: May 10, 2013
    Publication date: January 14, 2016
    Applicants: KAEL-GEMVAX CO., LTD.
    Inventor: Sang Jae KIM
  • Publication number: 20160002613
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Application
    Filed: September 17, 2013
    Publication date: January 7, 2016
    Applicant: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae KIM
  • Publication number: 20150353903
    Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 10, 2015
    Applicants: KAEL-GEMVAX CO., LTD.
    Inventor: Sang Jae KIM
  • Publication number: 20150307859
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Application
    Filed: September 17, 2013
    Publication date: October 29, 2015
    Applicant: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae KIM
  • Publication number: 20150175978
    Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a. superior effect of treating and preventing rheumatoid arthritis with minimized side effect.
    Type: Application
    Filed: May 10, 2013
    Publication date: June 25, 2015
    Applicants: KAEL-GEMVAX CO., LTD.
    Inventor: Sang Jae Kim
  • Publication number: 20150099692
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMBAX CO., LTD., GEMVAX AS
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 8614177
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: December 24, 2013
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Publication number: 20120269858
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 25, 2012
    Applicant: GEMVAX AS
    Inventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
  • Patent number: 8193326
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 5, 2012
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Publication number: 20110105721
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 5, 2011
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Patent number: 7863244
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: January 4, 2011
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Patent number: 7794723
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: September 14, 2010
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
  • Patent number: 7375117
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: May 20, 2008
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Patent number: 7192927
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: March 20, 2007
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Publication number: 20070004632
    Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.
    Type: Application
    Filed: August 3, 2006
    Publication date: January 4, 2007
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
  • Publication number: 20060194731
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: March 29, 2006
    Publication date: August 31, 2006
    Applicant: GemVax As
    Inventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Eriksen
  • Patent number: 7078416
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: July 18, 2006
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Publication number: 20060106196
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Application
    Filed: January 17, 2006
    Publication date: May 18, 2006
    Applicant: GemVax AS
    Inventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal, Stein Saeboe-Larsen
  • Patent number: 7030211
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: June 30, 1990
    Date of Patent: April 18, 2006
    Assignee: GemVax AS
    Inventors: Gustay Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen